

# 2023 Spring Conference

Mon 24th - Wed 26th April

Sage, Gateshead



#BHIVA23

Follow us on social media







The Gilead-HIV.co.uk website is intended for UK and Ireland Healthcare Professionals. The website contains promotional content.





**Gilead-HIV.co.uk** is a website for healthcare professionals to access our product information, and other content including articles, webinars, and resources to support the clinical management of people living with HIV. You can access our website by clicking or scanning the QR code below.



©Gilead 2009-2022. The Gilead-HIV.co.uk website is funded and developed by Gilead Sciences Ltd. Registered in England (No. 02543818). All rights reserved. UK-UNB-3606 | Date of preparation March 2023.



# LIVING WELL WITH HIV IS NOT ONE-SIZE-FITS-ALL. TREATMENT SHOULDN'T BE EITHER.

ViiV Healthcare's innovative portfolio of medicines provides options—because individualising care for people living with HIV matters, to you and to us.



# Welcome



Professor Yvonne Gilleece Chair, British HIV Association (BHIVA)

# A massive welcome to you all for the BHIVA Spring Conference in Gateshead!

We are still enjoying the novelty of face-to-face conferences and hope you are too, with the opportunity not only of learning but to network with colleagues and friends.

We have a comprehensive programme of sessions on important HIV-related comorbidities, health and psychological wellbeing as well as patient related outcome measures which we hope you will enjoy. We will also present the results of our Equality, Equity, Diversity and Inclusion review, to which many of you have contributed to - thank you.

We have social events at the end of each day on Monday and Tuesday and really hope to see you there.

This event would not be possible without the hard work and dedication of our speakers and committee members, with a very special mention for our conferences chair Dr Nicky Mackie, who once again has overseen a programme to be proud of. We must of course thank our sponsors for their continued and generous support of BHIVA, which assists greatly with the running of this conference and keeping costs down for BHIVA members.

So do please enjoy, learn and have fun!

### Professor Yvonne Gilleece

Chair, British HIV Association (BHIVA)



# **Contents**

Badges must be worn at all times in order to gain access to the lecture theatre, exhibition and catering areas.

BHIVA committees	6
Conference information	7
Social events	11
Awards and Scholarships	12
Spring Conference Programme	13
Poster abstracts	18
Programme of satellite symposia and sponsors' workshops	26
Speakers biographies	29
Sponsors and exhibitor biographies	40
Speaker's conflicts of interest	49
Exhibition floor plan and exhibitors	50





# **BHIVA Committees**

### **BHIVA Executive Committee**

### Chair

Professor Yvonne Gilleece, Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust

### Vice Chair

Dr Nicola Mackie, Imperial College Healthcare NHS Trust, London

### **Honorary Treasurer**

Dr Iain Reeves, Homerton University Hospital,

### **Honorary Secretary**

Dr Tristan Barber, Royal Free London NHS Trust

### **EXECUTIVE MEMBERS**

Dr David Chadwick, James Cook University Hospital, Middlesbrough

Dr Daniel Clutterbuck, NHS Lothian

Dr Ashini Fox, Nottingham University Hospital

Dr Nick Larbalestier, Guy's and St. Thomas' NHS Foundation Trust

Dr Jonathan Underwood, University Hospital of Wales

### New Consultant Doctors' Representative

Dr Rebecca Metcalfe, NHS Greater Glasgow and Clyde

### Trainee Doctor's Representative

Dr Manik Kohli, Mortimer Market Centre

### **HIV Medicine Editor Trustee**

Professor Caroline Sabin, University College London

### **UK-CAB** Representative

Ms Jo Josh, UK Community Advisory Board

### Financial Expert Trustee

Ms Paula Bibby, University of Cambridge

### **BHIVA Conferences Subcommittee**

### Chair

Dr Nicola Mackie, Imperial College Healthcare NHS Trust

### Vice Chair

Dr Laura Waters, Central and North West London NHS Foundation Trust

### **Members**

Mr Asim Ali, Guy's & St Thomas' NHS Foundation Trust

Dr Tristan Barber, Royal Free London

NHS Foundation Trust

Dr Ashini Fox, Nottingham University Hospital

Professor Yvonne Gilleece, Brighton & Sussex Medical School and University Hospitals Sussex

NHS Foundation Trust

Mr Hasan Mohammed, Chelsea & Westminster Hospitals NHS Trust

Dr Farai Nyatsanza, Cambridgeshire Community Services NHS Trust

Dr Matthew Page, University Hospitals Birmingham NHS Foundation Trust

Dr Iain Reeves, Homerton University Hospital NHS Foundation Trust, London

Professor Caroline Sabin, University College London

### **UK-CAB** Representative

Ms Jo Josh, UK Community Advisory Board

### **Local Host**

Dr Ashley Price, The Newcastle Upon Tyne Hospitals NHS Foundation Trust

### Oral research judging panel

Professor Caroline Sabin, University College London (Chair)

Professor Fiona Burns, University College London

Professor Yvonne Gilleece, Royal Sussex County Hospital, Brighton

Dr Nicola Mackie, Imperial College Healthcare, London

Dr Iain Reeves, Homerton University Hospital, London

Dr Jonathan Underwood, University Hospital of Wales

Dr Laura Waters, Mortimer Market Centre

### Poster presentation judging panel

Dr Tristan Barber, Royal Free London

NHS Foundation Trust (Chair)

Dr Clare van Halsema, Manchester University NHS Foundation Trust (Deputy Chair)

Dr Nadia Ahmed, Central North West London NHS Trust

Dr Douglas Fink, University College London

Dr Ashini Fox, Nottingham University Hospital

Ms Jo Josh, UK Community Advisory Board

Dr Manik Kohli, Mortimer Market Centre

Dr Rebecca Metcalfe, NHS Greater Glasgow and Clyde

Nadia Naous. Chelsea and Westminster

NHS Foundation Trust

Dr Matt Page, University Hospitals Birmingham NHS Foundation Trust



# **Conference Information**

### Venue

Sage Gateshead St Mary's Square, Gateshead Quays Gateshead, NE8 2JR T: 0191 443 4669

W: www.sagegateshead.com

### **Exhibition**

The exhibition represents an integral element of the conference, providing participants with an excellent platform for networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare solutions, and services within the field of HIV and GU medicine. Entrance to the exhibition hall is free for all registered delegates.

### **Exhibition Opening Times**

Monday 24th April 08:00 – 19:30

(incl. Welcome Reception)

Tuesday 25th April 08:00 – 17:45 Wednesday 26th April 08:00 – 14:10

### **Getting Here**

Sage Gateshead is a 15–20-minute walk from Newcastle Central train station. There is also a taxi drop off point at the west entrance of Sage. There is car parking available for anyone driving to the venue (charges apply).

### Registration

Registration includes access to all scientific sessions, including satellite symposia, lunchtime parallel sessions, the exhibition area, refreshments and lunch for the days specified in your registration acknowledgement correspondence.

Please access the venue through the West Entrance of Sage Gateshead.

The registration desk is located in the Concourse of the ground floor of the venue and will be open during the following hours:

Monday 24th April 08:00 – 18:30 Tuesday 25th April 07:45 – 18:00 Wednesday 26th April 07:45 – 16:30

### **Delegate badges**

Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas.

### **Conference Sessions**

Plenary sessions will take place in Sage 1.

Parallel sessions over lunchtimes will take place in Sage 1 & 2 and the Barbour room.

Doors will open 15 minutes prior to the lunchtime

sessions and places are available on a first-come, first-served basis. No separate lunch will be provided for delegates attending workshops, however lunch will be available in the Concourse (exhibition) for the full duration of the lunch period and time has been allowed prior to the start of the lunchtime sessions, for delegates to have lunch.

### **Continuing Professional Development (CPD)**

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, pharmaceutical-supported sessions and social events). The unique reference code for the conference is 143589. The entire conference has been allocated 21 CPD credits. Please be advised that the attendance list of the conference will be forwarded to the Royal College of Physicians upon request.

### Social events

There are two social events: a Welcome Reception (Monday) to be held at the conference venue and a Social evening (Tuesday) to be held at By the River Brew Co., a 2-minute walk from the venue.

Tickets are required to gain entry to the Social Evening on Thursday. Please refer to page 9 of this programme for full details of the social events. If you have reserved a ticket but find that you cannot attend, please let the Conference Organiser know as soon as possible and return your ticket to the Registration Desk at your earliest convenience.



### Poster presentations

Posters will be displayed on the mezzanine outside Sage 1 and Sage 2 on Level 1 of the venue.

All poster boards will be numbered, and poster presenters should use the board displaying the number allocated to their poster.

Posters will be judged during the welcome reception 18:10 - 19:10 Monday 24th April, and poster authors are encouraged to stand by their posters during this time. A selection of poster authors will be invited to present their research in the Best Poster Session 09:55 Wednesday 26th April and poster prizes will be presented in the Closing Session of the same day.

### Speaker preview room

All presenters are reminded to ensure they visit the speaker preview room at least 3 hours in advance of their talk to check and sign off that we have the most up to date version of their slides. Speakers will be able to make final changes with the technicians here but will not be able to change their presentation in the auditorium or present from their own laptop.

The Speakers' Preview Room is located in the Squires Seminar Room

### WiFi

Free WiFi access is available throughout the conference venue.

### Cloakroom

A manned cloakroom is available onsite at the venue. All belongings are left at the owner's risk. The British HIV Association does not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom area.

### Filming and photography

Please note that all sessions held in Sage 1 will be filmed and uploaded to the BHIVA website following the event. In addition, some still photography will take place at the conference. This will include general coverage of registration, exhibition and workshop areas, as well as conference social events. This material may be published in BHIVA publications or on the BHIVA website and on BHIVA's social media pages.

### Liability and insurance

The Meeting Secretariat and Organisers cannot accept liability for personal accidents or loss or damage to private property of participants either during or indirectly arising from the BHIVA Spring Conference.

### Social Media

Follow BHIVA on social media. #BHIVA23



British HIV Association



BritishHIVAssociation



@BritishHIVAssoc

# Safety measures

The safety of delegates is our priority and we have worked with the venue to ensure we make the conference as safe as possible for everyone.

Whilst LFT testing is no longer a legal requirement we would like to encourage you to test prior to traveling to the conference. If you test positive or have any COVID or flu-like symptoms, please do not attend the conference and contact the secretariat to discuss the cancellation of your place.

# A multidisciplinary perspective on optimising HIV treatment regimens

British HIV Association Spring Conference 2023 Wednesday 26th April 11.15am-12.15pm, Sage 1





Chair, Consultant **Dr Steve Taylor** 



Consultant **Dr Claire Dewsnap** 



Practitioner

Hasan Mohammed

**Pharmacist** 



Clinical Nurse

ner Specialist

Jonathan Roberts

Promotional satellite symposium sponsored by MSD. This meeting is organised and fully funded by MSD. For UK healthcare professionals only.

MSD products will be discussed at this meeting. Prescribing information and adverse event reporting information will be available at the meeting.

Merck Sharp & Dohme (UK) Limited

Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

GB-DOR-00441 | Date of preparation: March 2023





# JOIN BHIVA

# Key benefits for UK and international members

Discounted conference registration.

Online account with access to the BHIVA members' area, including e-learning modules, webcasts and the latest issue of the HIV Medicine journal.

Eligibility for awards and scholarships and voting in BHIVA elections.

www.bhiva.org/Membership





# **Social Events**

# **BHIVA Welcome Reception**

Please join us for the Welcome Reception on Monday 24th April 2023

This event will take place from: 18:10

In the: Conference Venue, Sage, Gateshead

Please join us for a drink and some nibbles after our first day at Conference.

This event is free to attend.

# **BHIVA Social Evening**

Please join us for the BHIVA Social Evening on **Tuesday 25th April 2023** 

This event will take place from: **7pm** 

At: By the River Brew Co., Hillgate Quays, Gateshead, NE8 2FD

The evening will be an informal opportunity for people to come together, with food, welcome drinks, music and dancing! (and a cash bar operating all evening).

Tickets cost: £35 per person and can be purchased in advance or at the registration desk (while still available).







# Awards and Scholarships

### **Awards**

# The BHIVA Margaret Johnson Best Oral Research Presentation

This prize will be awarded to the presenter of the best oral research presentation during the conference. All oral research presentations will be judged by a BHIVA-appointed oral research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Wednesday 26th April.

# The BHIVA Ian Williams Best Poster Presentation

This prize will be awarded to the presenter of the best poster research presentation during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Wednesday 26th April.

### Chloe Orkin and Martin Fisher Awards

Two prizes will be awarded for the best oral or poster research presentation during the conference in the field of social sciences and community-based work. The awards will be presented at the Prizes and Awards Ceremony on Wednesday 26th April.

### The BHIVA Best Case Presentation

A prize will be awarded to the presenter of the best case presentation as part of the BHIVA Clinico-pathological case presentations session. The prizes will be presented at the Prizes and Awards Ceremony on Wednesday 26th April.

### **Commended Oral Presentations**

Up to three awards will be presented in recognition of the best oral research presentations during the conference. To be eligible for these prizes the presenter must be of junior grade (sub-consultant or equivalent). All oral presentations will be judged by a BHIVA-appointed oral research judging panel. The awards will be acknowledged during the Prizes and Awards Ceremony on Wednesday 26th April.

### **Commended Poster Presentations**

Up to 15 awards will be presented in recognition of the best poster research presentations during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel. A rosette will be awarded to the top 15 posters after the poster judging session during the Welcome Reception. The awards will be acknowledged during the Prizes and Awards Ceremony on Wednesday 26th April.

### **Scholarships**

### **BHIVA Science Scholarships**

Science Scholarships have been awarded up to 10 researchers and scientists whose abstracts have been accepted for presentation. All registration fees and a contribution towards travel and the cost of accommodation for up to three nights are covered by BHIVA.

### **BHIVA Community Registration Support**

BHIVA have supported up to 50 registration places from community and affiliated organisations in order to assist with attendance at conference

### **BHIVA Community Scholarships**

BHIVA Community Scholarships have been awarded to up to 10 UK-based community registrants. All registration fees and a contribution towards accommodation for up to three nights have been covered by BHIVA. In addition, a contribution is offered by BHIVA towards travel expenses.

# BHIVA Registration Scholarships- supported by Gilead Sciences

Registration Scholarships have been awarded to up to 10 delegates who are either retired, not working or employed in a part-time capacity. Places are also allocated to students involved in full-time undergraduate or post-graduate work. The scholarship covers the conference registration fee.

# Healthcare Professional Registration Support - supported by Gilead Sciences

Registration fee support was awarded to up to 40 healthcare professionals whose professional position was judged as aligned to the conference (This applied to all MDT members and was not limited to doctors).



# Scientific Programme

### **MONDAY 24 APRIL 2023**

09:00 - 09:10 Welcome & Introduction by the Chair of BHIVA Sage 1 Yvonne Gilleece, Brighton & Sussex University Hospitals NHS Trust 09:15 - 09:55 Navigating new pandemics: what have we learnt Sage 1 Chair: Yvonne Gilleece, Brighton & Sussex University Hospitals NHS Trust Susan Hopkins, UK Health Security

10:00 - 10:40 Of Pandemics and Wars Sage 1 Chair: Clare van Halsema, Manchester University NHS Foundation Trust Sanjay Bhagani, Royal Free London NHS Foundation Trust, UK

Agency

10:40 - 11:10 Break the concourse (ground floor exhibition area)

11:10 - 12:10 **HIV and Resistance Sage 1** Chair: Nicola Mackie, Imperial College Healthcare NHS Trust

> Public health approach to HIV treatment and the impact of drug resistance

Nick Paton, National University of Singapore

**Highly Treatment Experienced:** what it means & best management Laura Waters, Mortimer Market Centre, London

12:15 - 13:15 Oral abstracts session one Sage 1

Chairs: Caroline Sabin, University College London & Michael Ewens, Leeds Teaching Hospitals NHS Trust

**O01** Microelimination of hepatitis C among people living with diagnosed HIV in England

James Lester, UK Health Security Agency,

O02 Laboratory implementation of Emergency Department Blood-Borne Virus (EDBBV) opt out screening in a London tertiary centre

Jennifer Hart, Royal Free London NHS Foundation Trust, UK

003 A review of sexual health and blood borne virus care provided to inmates at admission into UK prisons and secure facilities

Natasha Bell, Imperial College Healthcare NHS Trust, UK

**O04** Implementation of routine opt-out Blood Borne Virus (BBV) screening in 34 Emergency Departments (EDs) in areas of extremely HIV prevalence in **England** 

Rachel Hill-Tout, NHS England, UK

O05 Impact and experiences of offering HIV testing across the whole city population through primary care clusters and GP surgeries in the Texting 4 Testing (T4T) project

Darren Cousins, Fast Track Cities Cardiff & Vale, UK

13:15 - 14:25 Lunch & Exhibition the concourse (ground floor exhibition area)

13:40 - 14:25 **Parallel session** 

> **Building international partnerships** online and in person: lessons from Indonesia and Nigeria Sage 1

Chairs: Douglas Fink, Royal Free London NHS Foundation Trust & Nadia Ahmed, Central and North West London NHS Foundation Trust

Keerti Gedela, Chelsea and Westminster Hospital NHS Foundation Trust

Tomilola Musari-Martins Nigerian Institute of Medical Research, Lagos, Nigeria (remote speaker)

Sponsored workshop -ViiV Healthcare Sage 2

**Parallel session** 

Implementation of routine opt-out Blood Borne Virus (BBV) screening in Emergency Departments (EDs)

**Barbour room** 

Rachel Hill-Tout, NHS England

Orla McQuillan, Manchester Foundation Trust

Ian Jackson, NHS England Stephen Hindle, NHS England



### **MONDAY 24 APRIL 2023 CONTINUED**

14:30 - 15:30 Sponsored Satellite Symposium – Gilead Sciences Sage 1

15:35 - 16:35 Oral abstracts session two Sage 1

**Chair:** Tristan Barber, Royal Free London NHS Foundation Trust & Fiona Windebank, Leeds Teaching Hospitals NHS Trust

O06 'Not PrEPared' – Barriers to accessing PrEP in England

Adam Freedman, National AIDS Trust,

OO7 HIV care during the SARS-COV-2 pandemic in black people with HIV in the UK

Zoe Ottaway, Kings College Hospital NHS Foundation Trust, UK

O08 Clinical presentation of mpox in people with and without HIV

Michael Brady, King's College Hospital NHS Foundation Trust, UK

O09 "If you don't know, how can you know?": A qualitative investigation of HIV Pre-exposure prophylaxis knowledge and perceptions among women in England

Melissa Cabecinha, University College London, UK

O10 Sexually acquired young adults with HIV - a neglected cohort?

Sophie Herbert, Northamptonshire Healthcare NHS Foundation Trust, UK

16:35 - 17:10 Break the concourse (ground floor exhibition area)

17:10 - 18:10 Clinico-pathological case presentations Sage 1

**Chairs:** Ula Mahadeva, Guy's & St Thomas' NHS Foundation Trust, UK and Mark Bower, Chelsea & Westminster Hospital, UK

Case One - The hard cell: difficult diagnostics in a complex case

Meredith Moodie, North Middlesex University Hospital NHS Trust

Case Two - An unusual cause of headache

Nivenjit Kaur, King's College Hospital NHS Trust

Case Three - Vanishing Bile Duct Syndrome

Kinjal Patel, Imperial College Healthcare NHS Trust/ Chelsea and Westminster Hospital NHS Foundation Trust Case Four - Disseminated infection with new onset of neurological symptoms in a newly diagnosed HIV patient

Wai Lin Htun, Blackpool Teaching Hospital NHS Foundation Trust

Close, poster viewing & Welcome Reception

18:10 - 19:10

The concourse, ground floor & the mezzanine outside Sage 1 and Sage 2

Mon 24th - Wed 26th April 2023



### **TUESDAY 25 APRIL 2023**

08:00 - 08:45 Sponsored Satellite Symposium – Janssen Sage 1

08:50 - 10:15 The Care Cascade: where should we focus next? Sage 1

**Chairs:** Ashley Price, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK & John Jaquiss, UK Community Advisory Board

Overview of the cascade: where should we focus next?

Ann Sullivan, Chelsea and Westminster Hospital NHS Foundation Trust, UK

People living with HIV not in care: time to act!

Kate Childs, Kings College Hospital, UK

People living with HIV not in care: how can the data help?

Veronique Martin, UK Health Security Agency (UKSHA)

Joint panel Q&A

10:15 - 10:45 Break the concourse (ground floor exhibition area)

10:45 - 12:00 **PROMs Sage 1** 

**Chairs:** Richard Harding, Kings College London, UK & Jo Josh, UK Community Advisory Board

An overview of patient-reported outcome measures

Diana Barger, University of Bordeaux,

Evidence for PROMs in HIV care

Daniella Chilton, Guy's and St Thomas' NHS Foundation Trust, UK

The use of PROMs in clinical trials

Professor Caroline Sabin, University College London, UK

Embedding PROMs in BHIVA standards, what needs to happen

Fiona Burns, University College London / Royal Free Hospital, UK

Joint panel Q&A

12:05 - 13:05 Oral abstracts session three Sage 1

**Chairs:** Matt Page, University Hospitals Birmingham NHS Foundation Trust, UK & Alice Parsloe, University Hospitals Birmingham NHS Trust, UK

O11 Diabetes and hypertensive disorders in pregnant women living with HIV in the UK and Ireland

Laurette Bukasa, Integrated Screening Outcomes Surveillance Service (ISOSS), UK O12 Monitoring clinical practice of BHIVA supported breastfeeding guidelines for women living with HIV in the UK

Rebecca Sconza, Integrated Screening Outcomes Surveillance Service (ISOSS), LIK

O13 Antiretroviral therapy (ART) inhibits the growth of cervicovaginal microbiome species in vitro: potential role in preterm birth (PTB)

Veronica Georgiana Preda, Imperial College London, UK

O14 Comparison of pregnancy outcomes for mothers living with perinatally acquired HIV, behaviourally acquired HIV, and those not living with HIV

Shivani Shah, Imperial College Healthcare NHS Trust, UK

O15 High-risk HPV prevalence and serostatus in women living with perinatally acquired HIV (the SHiP study)

Tamara Elliott, Imperial College London, UK

13:05 - 14:30 Lunch & Exhibition the concourse (ground floor exhibition area)

13:35 - 14:20 **Parallel session** 

Tablet tales - myths, misconceptions and other patient questions Sage 1

Chair: Nicoletta Policek, UK-CAB

Ewan Hunter, The Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK Becky Walker, Blue Sky Trust, UK Mark Ellerby-Hedley, Newcastle upon Tyne Hospitals, UK

Sponsored workshop Gilead Sciences Sage 2

**Parallel session** 

Syphilis: Still Surprising Us Barbour room

**Chair:** Stuart Flanagan, BASHH HIV-BBV SIG Chair Victoria Appleby, Leeds Teaching

victoria Appleby, Leeds Tedal

Hospitals, UK

Kate Flanagan, King's College London, UK



### **TUESDAY 25 APRIL 2023 CONTINUED**

14:35 - 15:35 Sponsored Satellite Symposium – ViiV Healthcare Sage 1

15:40 - 16:40 Oral abstracts session four Sage 1

**Chairs:** Rebecca Metcalfe, NHS Greater Glasgow and Clyde, UK & Manik Kohli, Central and North West London NHS Foundation Trust, UK

O16 Lenacapavir with bNAbs teropavimab (3BNC117-LS) and zinlirvimab (10-1074-LS) dosed every 6 months in people with HIV Neal Marshall, Gilead Sciences, Ltd, London, UK

O17 Rate of persistent depressive symptoms among participants in the Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) study

Hajra Okhai, University College London, UK

O18 Prevalence of transmitted drug resistance among adults newly diagnosed with a recent HIV infection: a national survey

Anna Maria Geretti, University of Rome Tor Vergata, Italy

O19 Waist circumference cut-offs for metabolic syndrome and insulin resistance in women and men of African ancestry living with HIV

Laura Ribeiro Cechin, King's College Hospital NHS Foundation Trust, UK

O20 Eligibility for long acting cabotegravir/ rilpivirine in youth aged 12-25 living with perinatally-acquired HIV

Sara Ayres, Imperial College Healthcare NHS Trust, UK

16:40 - 17:10 Break the concourse (ground floor exhibition area)

17:10 - 18:00 Longer-term safety of integrase inhibitors Sage 1

**Chair:** Jonathan Underwood, University Hospital of Wales, UK

Andrew Carr, St Vincent's Hospital,

Sydney, Australia

18:00 Close

19:00 Gala social event

By the River Brew Co. (tickets only)

### **WEDNESDAY 26 APRIL 2023**

08:00 - 08:55 Themed Poster session Sage 1

**Chairs:** Alan Winston, Imperial College London, UK

Nadia Naous, Chelsea and Westminster Hospital NHS Foundation Trust, UK

TPO1 Blueteq is not just about cost, it's an opportunity to optimise antiretroviral therapy

Sinead Peare, Guy's and St Thomas' NHS Foundation Trust, UK

TPO2 Opportunities to improve optout blood-borne virus screening in two large London Emergency Departments Cassandra Fairhead, Royal Free London NHS Foundation Trust, UK

TPO3 Patient evaluation of Klick, a technology enabled, nurse delivered HIV outpatient pathway

Caroline Rae, Chelsea and Westminster Hospital, UK

TPO4 An innovative, patient centered approach to delivery of long-acting injectable antiretroviral therapy to people living with HIV using pre-existing outpatient parenteral antimicrobial therapy (OPAT) services Bazga Ali, Public Health Wales, Cardiff, LIK

TPO5 Addressing the Workforce Challenge: Role of the Advanced Pharmacist Practitioner (APP)

Hasan Mohammed, Chelsea & Westminster Hospital NHS Foundation Trust, UK

TP06 Integrating peer support within NHS clinics - a London Fast-Track Cities Initiative (FTCI) project Garry Brough, Positively UK

09:00 - 09:50 Providing mental health care and wellbeing in HIV: Learnings from the field Sage 1

**Chair:** Iain Reeves, Homerton Healthcare NHS Foundation Trust, UK

Updating the Standards for Psychological Support for Adults Living with HIV: Results of the stakeholder pre-consultation

Sarah Rutter, Manchester University NHS Foundation Trust, UK & Hajra Okhai, University College London, UK

Recent updates in the provision of addiction treatment

Andrea Hearn, Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK



### **WEDNESDAY 26 APRIL 2023 CONTINUED**

09:55 -10:45 Best poster session Sage 1

**Chairs:** Tristan Barber, Royal Free London NHS Foundation Trust, UK and Clare van Halsema, Manchester University NHS Foundation Trust, UK

10:45 - 11:15 Break the concourse (ground floor

exhibition area)

11:15 - 12:15 Sponsored Satellite Symposium -

MSD Sage 1

12:20 - 13:20 BHIVA Equality, Equity, Diversity

**Chairs:** Rageshri Dhairyawan, Barts Health NHS Trust, UK and Tristan Barber, Royal Free London NHS Foundation

and Inclusion Session Sage 1

Trust, UK

Background to EEDI work

Rageshri Dhairyawan, Barts Health  $\operatorname{NHS}$ 

Trust, UK

BHIVA: Equity, Equality, Diversity and Inclusion Review Update

Melvina Woode Owusu, Purple Pen Research and Evaluation Consulting, UK

Joint panel Q&A

Plan of action and future work

Tristan Barber, Royal Free London NHS

Foundation Trust

13:20 - 14:30 Lunch & Exhibition the concourse

(ground floor exhibition area)

13:35 - 14:20 **Parallel session** 

Sharing from Chiva oral history project 'Positively Spoken' Sage 1

Chair: Amanda Ely, Chiva

Wendy Rickard, Chiva & Ruth

Mukonoweshuro, Chiva

**Parallel session** 

People living with HIV not in care: logistics and disclosure Sage 2

Chair: Goli Haidari, Guy's and St

Thomas' NHS Trust, UK

Lucy Wood, Lewisham and Greenwich

NHS Trust, UK

Rose Mower, Guy's &St Thomas'

Hospital NHS Trust, UK

Hannah Alexander, North Middlesex University Hospital NHS Trust, UK

Melanie Rosenvinge, Lewisham and

Greenwich NHS Trust, UK

**Parallel session** 

Reviewing papers: what to look for in Real-World Evidence (RWE)

studies? Barbour room

Caroline Sabin, University College

London, UK

14:30 - 15:20 Clinical session Sage 1

Chair: Ashini Fox, Nottingham University

Hospital, UK

Absolute risk and benefits of interventions related to

cardiovascular disease

Neil Poulter, Imperial College London, UK

Malignancy – what's new in lung

cancer?

Qamar Ghafoor, University Hospitals

Birmingham NHS Foundation Trust, UK

15:25 -16:00 Awards and Close



### ANTIRETROVIRALS: EFFICACY, INTERACTIONS & PHARMACOKINETICS

### **P001**

Efficacy, Safety and Tolerability of Biktarvy in HIV-1 infection: A Scoping Review

Ellen Peters, Brighton and Sussex Medical School, UK

### P002

Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide Chloe Orkin, Queen Mary University of London, UK

### P003

Week 52 subgroup efficacy of lenacapavir in heavily treatment-experienced people with HIV Cindy Elliott, Gilead Sciences Ltd, UK

### P004

24-Month (24M) effectiveness and safety of bictegravir/emtricitabine/tenofovir Alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people living with HIV in the BICSTaR study

Marta Boffito, Chelsea and Westminster Hospital, UK

### P005

Switching to high genetic-barrier integrase inhibitors reduces drug-drug interactions in people living with HIV

Chhavi Nashier, Imperial College London, UK

### P006

Successful implementation of a novel treatment strategy: challenges, outcomes and patient perspectives

Kate Holland, Walsall Healthcare NHS Trust, UK

### **P007**

Outcome of National ARV Procurement, University Hospitals of Leicester

Iain Stephenson, University Hospitals of Leicester NHS Trust, UK

### **P008**

A retrospective review to identify acceptability of doravirine containing regimens in our single centre cohort of people with HIV (PWH)

Gavin Marshall, Royal Free London NHS Foundation Trust, UK

### P009

Switching to Biktarvy®: real world single centre outcomes over 3 years

Lisa King, Imperial College Healthcare Trust, UK

### P010

Total lymphocyte and CD4+ T-cell count changes in participants receiving islatravir (0.25mg, 0.75mg, and 2.25mg once daily) and doravirine±lamivudine: post hoc analysis from a phase 2b dose-ranging study (P011)

Rima Lahoulou, MSD France, France

### P01

Sequencing of low viral load HIV for drug resistance associated mutations

Anjna Badhan, Imperial College London, UK

### P012 - WITHDRAWN

Has switching off efavirenz-based antiretroviral therapy positively affected our patient cohort, with a focus on lipids and mental health outcome?

Pegah Soltanpoor, Kings College London, UK

### P013

A multi-centre audit of changes to renal function and weight following a switch from tenofovir disoproxil fumarate to tenofovir alafenamide Emily Boardman, The Northern Contraception, Sexual Health & HIV Service, UK

### P014

Review of Protease inhibitor use in our single site clinic for people living with HIV (PLWH)

Pedro Simoes, Royal Free London NHS Foundation Trust, UK

### P015

Effectiveness of dolutegravir + lamivudine in realworld studies in people with HIV-1 with M184V/I mutations: a systematic review and meta-analysis Tristan Barber, Royal Free London NHS Foundation Trust, UK

### P016

Characteristics and reasons for switch to Biktarvy in a large clinical cohort.

Hao Gao, University College London Medical School, UK

### P017

What influences acceptability of long-acting injectable ART and treatment setting: preliminary qualitative findings from the ILANA trial

Rosalie Hayes, Queen Mary University of London, UK

### P018

Single centre review of rapid antiretroviral therapy initiation during the COVID-19 pandemic

Michael Ewens, Leeds Teaching Hospitals NHS Trust, UK

### P135

5-year outcomes of bictegravir-emtricitabinetenofovir alafenamide (B-F-TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomised clinical trials

Chloe Orkin, Queen Mary University of London, UK

### **THEMED POSTER**

### TP0

Blueteq is not just about cost, it's an opportunity to optimise antiretroviral therapy

Sinead Peare, Guy's and St Thomas' NHS Foundation Trust, UK



### **BASIC SCIENCE: IMMUNOLOGY, VIROLOGY & PATHOGENESIS**

Neutralising antibodies (NAbs) against SARS-CoV-2 in BNT162b2 vaccine recipients with a history of advanced HIV infection: cPass as a simpler alternative to gold-standard tests

Alessandra Ruggiero, University of Verona, Italy

Rapid HIV progression in patients with increased prevalence of unstable HLA-C variants

Alessandra Ruggiero, University of Verona, Italy

**Analysis of Broadly Neutralising Antibody** Resistance in Adolescents and Young People living with HIV

Panagiota Zacharopoulou, University of Oxford, UK

### BEHAVIOUR, TRANSMISSION AND PREVENTION

Do we need to further Improve quality of care for those on pre-exposure prophylaxis (PrEP) against acquiring HIV infection: findings from a PrEP clinic Ambika Puri, Walsall Manor Hospital, UK

### P023

Self-sourcing of HIV pre-exposure prophylaxis (PrEP) amongst service users of Sexual Health London (SHL), a large, regional online postal sexually transmitted infection (STI) testing service

Laura Stewart, Chelsea and Westminster Hospital, UK

The impact of policy support for HIV Pre-Exposure Prophylaxis use on the number of new HIV diagnoses among men who have sex with men: an interrupted time series analysis

Hongbo Jiang, Guangdong Pharmaceutical University, China

### P025

HIV Pre-Exposure Prophylaxis use on a global scale among men who have sex with men: a systematic review and meta-analysis

Hongbo Jiang, Guangdong Pharmaceutical University, China

### P026

Missed opportunities for Pre-Exposure Prophylaxis (PrEP) and outcomes of people acquiring HIV with previous or recent PrEP use

Stephanie Tyler, Guy's and St Thomas' NHS Foundation Trust, UK

### P027

Using survey data to estimate the number of gay, bisexual and other men who have sex with men living with HIV at higher risk of mpox infection in England

Veronique Martin, UK Health Security Agency, UK

Current PrEP provision does not align with women's preferences: Early results from a cross-sectional

survey investigating PrEP awareness, interest, and preferences among women in England

Melissa Cabecinha, University College London, UK

### P029

Provision to diagnose, treat and prevent HIV in secure facilities of incarceration across the United Kingdom

Katie Humphries, NHS Lothian, UK

A systematic review of qualitative research on recently acquired HIV

Emily Jay Nicholls, University College London, UK

### P031

Quantifying re-engagement of people in HIV care after 12 months of non-attendance in outpatient

Christina Nigrelli, St George's University Hospitals NHS Foundation Trust, UK

### P032

Barriers to and facilitators of hepatitis C virus testing and disclosure among gay, bisexual and other men who have sex with men: findings from online focus groups

Nina Vora, University College London, UK

### P033

Comparison between COVID-19 & monkeypox vaccine uptake in a diverse London HIV cohort

Alison Barbour, Croydon Sexual Health Centre, UK

Urgent clinical need for reimbursed F/TAF PrEP in England: A single integrated sexual health service's (ISHS) experience of funding F/TAF PrEP post solid organ transplantation

Michael Ewens, Leeds Teaching Hospitals NHS Trust, UK

Understanding barriers and facilitators to HIV care retention – a systematic review

Breda Patterson, Gilead Sciences Ltd, UK



### **CHILDREN AND PREGNANCY**

### P036

Setting the research agenda: involving mothers living with HIV in research on children born HIV-free in the UK

Laurette Bukasa, University College London Great Ormond Street Institute of Child Health, UK

### P037

# HIV vertical transmission in England: current challenges

Helen Peters, Integrated Screening Outcomes Surveillance Service (ISOSS), UK

### **P038**

# Current overview of paediatric follow-up of infants exposed to HIV in England

Kate Francis, Integrated Screening Outcomes Surveillance Service (ISOSS), UK

### P039

# Infant Postnatal Prophylaxis (PNP) following maternal viraemia during breastfeeding

Emily Lees, University of Oxford, UK

### P040

Infant feeding choices in women living with HIV since 2019: reflections on real world data from an inner city tertiary HIV antenatal service

Eleanor Hamlyn, Royal Free Hospital, UK

### P041

### Population-level paediatric HIV surveillance in England: the current picture

Gabriela Toledo, University College London Great Ormond Street Institute of Child Health, UK

### P042

A postnatal clinic for people living with HIV (PLWHIV), a specialist trainee led initiative to improve outcomes

Joseph Heskin, Chelsea and Westminster NHS Foundation Trust, UK

### P043

# Ethical considerations for non-disclosure of HIV status in pregnancy

Yasmin Walters, Chelsea and Westminster NHS Foundation Trust, UK

### P044

**'Don't forget the children' - even in a pandemic** Michael Ewens, Leeds Teaching Hospitals NHS Trust, UK

### CO-MORBIDITIES, CO-INFECTIONS AND HIV/ART COMPLICATIONS

### P045

# Significant weight loss in people receiving metformin and dolutegravir

Hannah Alexander, North Middlesex University Hospital, UK

### P046

Predictors of hepatitis B treatment response in people with HIV and HBV initiating treatment

Samm Kabagambe, Gilead Sciences Ltd, UK

### P047

Common adverse events in clinical studies of people using lenacapavir for HIV treatment

Ricky Tsang, Gilead Sciences Ltd, UK

### P048

Primary Effusion Lymphoma: a single-institution cohort study

Mark Bower, Centre for HIV Malignancy, UK

### PO49

Effect of low-dose oral vitamin d on bone mineral density changes in hiv patients: longitudinal prospective study for 6 years

Shyamalie Bopitiya, Coventry and Warwickshire Partnership Trust, UK

### **P050**

Cerebrospinal fluid HIV RNA and viral nucleic acid detection in persons with HIV

Manraj Bawa, Imperial College London, UK

### P051

Resolution of neuropsychiatric adverse events after switching to a doravirine-based regimen in the open-label extensions of the DRIVE-AHEAD and DRIVE-FORWARD trials

Rima Lahoulou, MSD France, France

### P052

Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen

Rima Lahoulou, MSD France, France

### P053

Associations between inflammatory profiles and multimorbidity burden among people living with

Caroline A Sabin, University College London, UK

### P054

Weight and body mass index changes in women receiving cabotegravir + rilpivirine long-acting or bictegravir in the SOLAR study

Parul Patel, ViiV Healthcare, Durham, USA



### P055

Risk factors for hepatic steatosis in people living with and without HIV: Evidence from the POPPY cohort study

Alejandro Arenas-Pinto, University College London, UK

### P056

Psychological wellbeing and sleep in human immunodeficiency virus (HIV)- a retrospective analysis of assessment and interventions within HIV services in the UK and Ireland (UKI)

Nicola Galbraith, Gilead Sciences Ltd, UK

### P057

COVID-19 vaccination rates in people living with HIV in North East England

Ben Sayer, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK

### P058

Co-morbidities in people living with HIV in the North-East who are unvaccinated against COVID-19: a descriptive study

Ben Sayer, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK

### P059

Tackling Hepatitis B co-infection in PLHIV after COVID: an Audit and updated guidelines

Hannah Alexander, North Middlesex University Hospital, UK

### P060

Clinical outcome of lopinavir/ritonavir as hiv second line treatment in single tertiary hospital in Malaysia

Kok Soon Lee, Hospital Sultanah Aminah, Johor Bahru, Malaysia

### P061

A collaborative approach to the management of neurological conditions in people living with HIV Kimiya Asjadi, Kings College Hospital, UK

### POA2

First description of Efavirenz as a cause of drug induced autoimmune hepatitis: compelling evidence from two cases

Amelia Oliveira, King's College Hospital, UK

### P063

Sight-threatening mpox in people living with wellcontrolled and advanced HIV: two case reports of mpox blepharokeratoconjunctivitis with prolonged viral shedding

Tatiana Bovill Rose, St George's Hospital NHS Foundation Trust, UK

### P064

A review of dolutegravir use and weight gain in a diverse HIV cohort in outer North-West London

Venkateshwaran Sivaraj, London North West University Healthcare NHS Trust, UK

### P065

Re-framing how frailty is identified, diagnosed and managed among people living with HIV: exploratory perspectives from clinical practice

Tristan Barber, Royal Free London NHS Foundation Trust, UK

### P066

The impact of the Covid-19 pandemic on cervical screening and outcomes for women living with HIV

Dona Rimanishta, Brighton and Sussex Medical School, Brighton, UK

### HIV TESTING, EPIDEMIOLOGY AND SURVEILLANCE

### P067

HIV Partner notification during the Pandemic - An audit of new diagnoses HIV diagnoses at a local clinic between Jan 2020 – Feb 2022

Vafie Sheriff, St Georges University of London, UK

### P068

Audit of missed opportunities in people diagnosed late with HIV and establishment of a review and feedback process for new late diagnoses

Clemency Nye, Cardiff and Vale University Health Board,

### P069

Implementing a late diagnosis review protocol for HIV across the southeast of England with a public health perspective: lessons for national roll-out Lucy Lynch, UK Health Security Agency, UK

### P070

Factors associated with severe SARS-COV-2 infection in people of black ethnicities living with

### HIV in the UK

Zoe Ottaway, Kings College Hospital NHS Foundation Trust, UK

### P071

Previous HIV testing rates amongst heterosexuals diagnosed HIV positive through Sexual Health London (SHL), an online postal sexually transmitted infection testing (STI) service

Gemma McDonald, Chelsea and Westminster Hospital, UK

### P072

Mortality among people with HIV in the UK in 2021: findings from the National HIV Mortality Review

Ammi Shah, UK Health Security Agency, UK

### D073

Viral suppression, linkage to care, and outcomes in those previously diagnosed abroad

James Lester, UK Health Security Agency, UK



### P074

Auditing BHIVA 2020 HIV testing guidelines in primary care in an area of extremely high HIV seroprevalence: A cross-sectional, regional questionnaire

Simisola Agunbiade, Chelsea and Westminster Hospital

### P075

An audit of new diagnoses of HIV in a deprived local authority – are we detecting HIV too late?

Chevonne van Rhee, Public Health Sandwell Metropolitan Borough Council, UK

### **P076**

Progress towards ending HIV transmission in England by 2030

Veronique Martin, UK Health Security Agency, UK

### P077

Trends in the number of people living with transmissible HIV in England, 2019–2021

Veronique Martin, UK Health Security Agency, UK

### **P078**

**HIV knowledge survey in a district hospital** Wai Lin Htun, Blackpool Teaching Hospital NHS Foundation Trust, UK

### P079

New diagnoses of HIV through multi-centre emergency department opt-out HIV testing

Farnaz Dave, North Manchester General Hospital, UK

### POSO

Higher late diagnosis among people diagnosed with HIV through emergency department opt-out testing programs at Ealing, Brent, and Harrow boroughs of London

Venkateshwaran Sivaraj, London North West University Healthcare NHS Trust, UK

### P081

Nurse led management of HIV results from Emergency Department opt-out testing

Jessica Pinto, Royal Free London NHS Foundation Trust, UK

### P082

Using implementation science to support the adoption of routine HIV testing in a suburban Emergency Department

Olubanke Davies, Epsom & St Helier University Hospitals NHS Trust, UK

### P083

Risk factors for HIV outcomes among people newly diagnosed with HIV in England

Andres Felipe Mora-Salamanca, University College London, UK

### P084

HIV outcomes differences between gay and bisexual Latin American migrants and other gay and bisexual populations in England

Andres Felipe Mora-Salamanca, University College London, UK

### P085

An assessment of a District General Hospital's (DGH) compliance to HIV screening guidelines, and an analysis of barriers to routine testing. Implementation of interventions towards improving routine screening

Chidera Chukwufumnanya Aligbe, Northern Care Alliance, UK

### P086

Clinical epidemiology of COVID-19 in black people with HIV in South London, UK

Zoe Ottaway, Kings College Hospital NHS Foundation Trust, UK

### P087

HIV testing in community settings in England: results from the 2021 survey

Neil Mackay, UK Health Security Agency, UK

### P088

UKHSA engagement data: a useful tool for HIV centres to identify patients not in care

Hannah Alexander, North Middlesex University Hospital, UK

### P089

Prevalence and presentations of HIV in asylum seekers in the London borough of Hounslow

Alissa Amrose, West Middlesex University Hospital, UK

### DOO

Comparing short-term mortality between people with and without HIV admitted to the intensive care unit, 2000-2019

Caroline A. Sabin, University College London, UK

### P091

How use of cut-off index (COI) helps clinicians manage reactive HIV test results that arise from service users accessing Sexual Health London (SHL), a regional STI/HIV postal testing service Sophie Jones, Chelsea and Westminster NHS Trust, UK

### P092

Campaigning for HIV/AIDS prevention: a community-led approach to widen access and uptake of HIV testing

Alessandro Ceccarelli, Fast Track Cardiff & Vale, UK

### P093

Service evaluation of the clinical impact of the blood bottle shortage on opt-out HIV testing in sexual health services and the uptake of online HIV self-testing

Jasmine Limbu, Cardiff University, UK



### **THEMED POSTER**

### **TP02**

Opportunities to improve opt-out blood-borne virus screening in two large London Emergency Departments

Cassandra Fairhead, Royal Free London NHS Foundation Trust, UK

### **PSYCHOSOCIAL ISSUES AND QUALITY OF LIFE**

### P094

Patients living with HIV (PLWH) not in care – what are the barriers to accessing treatment?

Ayoma Ratnappuli, King's College Hospital, UK

### P095

Towards positive practice - people living with HIV and experiences of primary care

Joshua Wharton, George House Trust, UK

### P096

Fifty Over 50 – a collection of individual reflections on growing older with HIV

Mike Newman, Merck Sharp & Dohme UK, UK

### P097

"Attitudes hadn't changed as much as I'd thought": Experiences of HIV Stigma in the North East of England

Kate Reilly, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK

### P098

Addressing internalised stigma in HIV clinics - a London Fast-Track Cities Initiative (FTCI) project

 $Harun\ Tulunay,\ Positively\ UK$ 

### P099

Measuring what matters: how do we assess sleep in HIV care?

Michelle Croston, University of Nottingham, UK

### P100 - WITHDRAWN

"I'm sorry I didn't attend; I was getting on with my life." A study of issues affecting people living with Human Immunodeficiency Virus (HIV) from engaging in care

Julie-Anne Field, Outpatients East Barking Hospital, UK

### P101

**Social prescribing for people living with HIV** Emily Edwards, University of Aberdeen, UK

### P102

'Start Making Sense': a qualitative exploration of a trauma psychoeducation group for people living with HIV

Kate Reilly, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK

### P103

How did the COVID pandemic impact anxiety and health anxiety in women living with HIV?

Joanne Mc Carthy, Positive East, UK

### P104

Stitch Sisters - Psychology outside the box

Joanne Mc Carthy, Positive East, UK

### P105

Addressing loneliness and dietary needs during the COVID-19 pandemic: experiences of people living with HIV receiving support from a small HIV support organisation

Gary Pargeter, Lunch Positive, UK

### **SERVICE DEVELOPMENT, EDUCATION & TRAINING**

### **THEMED POSTERS**

### TPO3

Patient evaluation of Klick, a technology enabled, nurse delivered HIV outpatient pathway

Caroline Rae, Chelsea and Westminster Hospital, London, UK

### **TP04**

An innovative, patient centered approach to delivery of long-acting injectable antiretroviral therapy to people living with HIV using pre-existing outpatient parenteral antimicrobial therapy (OPAT) services

Bazga Ali, Public Health Wales, Cardiff, UK

### TP05

Addressing the Workforce Challenge: Role of the Advanced Pharmacist Practitioner (APP)

Hasan Mohammed, Chelsea & Westminster Hospital NHS Foundation Trust, UK

### TP06

Integrating peer support within NHS clinics - a London Fast-Track Cities Initiative (FTCI) project

Garry Brough, Positively UK, London, UK



### P107

Audit outcomes of nurse delivered care within Klick, a technology enabled, outpatient pathway for people living with HIV (PLWH)

Rebecca Wilkins, Chelsea and Westminster Hospital, UK

### P108

Latent TB screening in people living with HIV within Rochdale, Greater Manchester

Siew Yan Teo, HCRG Care Group - ORB, UK

### P109

An audit of uptake of flu, COVID-19 and pneumococcal vaccines in a cohort of people living with HIV

Nicoll Butter, University of Aberdeen, UK

### P110

Retaining patients in care: a multidisciplinary team (MDT) approach for patients who do not attend clinic (DNA) on the day

Goli Haidari, Guy's & St Thomas' NHS Foundation Trust, UK

### P111

The use and utility of toolkits in supporting cabotegravir + rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study

Rekha Trehan, ViiV Healthcare, UK

### P112

'More taboo than talking about drugs' - a qualitative assessment of the sexual health needs of people who inject substances in Greater Glasgow and Clyde

Claire Kofman, Waverley Care, UK

### P113

Knowledge of HIV and attitudes towards people living with HIV amongst hospital healthcare workers

Linda Cheyenne Vaccari, Royal Free London NHS Foundation Trust, UK

### P114

Outpatient parenteral antimicrobial therapy (OPAT) service delivery of long-acting antiretrovirals – clinical staff and patient-reported outcome measures (PROMs)

Thomas George, Cardiff and Vale University Health Board, UK

### P115

Examining HPV related cancer screening and vaccination rates amongst women in a large HIV service

Chloe White, University College London Medical School,  $\operatorname{\mathsf{UK}}$ 

### P116

Examining HPV related cancer screening and vaccination rates amongst MSM in a large HIV service

Chloe White, University College London Medical School, UK

### P117

Long Acting injectable Antiretrovirals (LAI-ARVs)
– Multidisciplinary team (MDT) outcomes from a
large London HIV service

Bhavna Halai, Guy's and St Thomas' NHS Foundation trust, UK

### P118

**Experiences of Establishing a Long-Acting Injectable (LAI) Anti-Retroviral (ARV) Clinic**Bhavna Halai, Guy's and St Thomas' NHS Trust, UK

### P110

The stable patient pathway (SPP) one year onreduced monitoring and patient initiated follow up (PIFU) for stable patients in a London HIV outpatient department

Zareena Mahomed, Guy's & St. Thomas' NHS Foundation Trust, UK

### P120

User experience of an in-clinic pre-exposure prophylaxis (PrEP) service

Eliot Hurn, Lewisham and Greenwich NHS Foundation Trust, UK

### P121

A three-cycle quality improvement project to improve HIV testing for patients presenting with indicator conditions to acute medicine in Gateshead, UK

Alexander Martin, Gateshead Health NHS Foundation Trust, UK

### P122

Is hepatitis c screening worthwhile? an investigation into hepatitis c screening in cumbria's sexual health clinics

Jason Niblett, North Cumbria Integrated Care NHS Trust, UK

### P123

What happens after reengagement? Outcomes of PLWH linked back into care through a dedicated SE London program

Kate Childs, King's College Hospital NHS Trust, UK

### D124

A collaborative approach to research study recruitment in PLWH during the SARS CoV-2 pandemic

Katherine Spears, Royal Free London NHS Foundation Trust, UK



### P125

How many patients will require Tenofovir Alafenamide (TAF) based HIV pre-exposure prophylaxis?

Rebecca Coltart, University of Glasgow, UK

### P126

Quality of transfer letters for patients moving HIV providers in the UK

Michael Ward, Calderdale and Huddersfield NHS Trust, UK

### P127

Cost-effectiveness of switching antiretroviral therapy to British HIV Association recommended regimens

Aidan Ireland, South Tees Hospitals NHS Foundation Trust, UK

### P128

What is the new normal? Frequency of monitoring after COVID-19

Brendan Payne, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK

### P129

Post-exposure prophylaxis for sexual exposure (pepse) prescriptions in the era of pre-exposure prophylaxis (prep)

Harsha Moolchandani, MPFT, UK

### P130

Is the switch worth it? How changing from noncommissioned antiretrovirals has affected cost and pill burden in a single centre

Theodora Voitcu, The Newcastle upon Tyne Hospitals Foundation Trust, UK

### STI, REPRODUCTIVE HEALTH, CONTRACEPTION & SEXUAL DYSFUNCTION

### P131

Review of the characteristics of Syphilis cases over 10 years in an inner-city urban cohort

Wai Lin Htun, Blackpool Teaching Hospital NHS Foundation Trust, UK

### P132

Characteristics and outcomes of Mpox infection in people living with Human Immunodeficiency Virus (PLWHIV)

Anna Garder, The Northern Integrated Contraception, Sexual Health and HIV Service, UK





# Industry Satellite Symposia & Workshops

### **MONDAY 24 APRIL 2023**

### 13:40 – 14:25 **Workshop** sponsored by ViiV Healthcare



Title: Life starts at 40... 61 years Chair: Professor Mark Nelson. Chelsea and Westminster

Speakers: Dr Lauren Walker,

Liverpool

Paul Clift, Community representative Specialist Nurse Michelle Mussard, Liverpool

Dr Ming Jie Lee, Imperial College of London

### 14:30 – 15:30 Satellite Symposium **GILEAD** sponsored by



**Gilead Sciences** Title: Confidence Matters - The Impact of ART choice on Weight and Metabolic Health

Chair: Dr Laura Waters, Consultant Physician HIV & Sexual Health, CNWL NHS Trust, London

Speakers: Dr Graeme Moyle, Consultant Physician and HIV Specialist, Chelsea and Westminster Hospital

Dr Daniella Chilton, Consultant in HIV and Genitourinary Medicine, Guy's and St Thomas' Hospital

### **TUESDAY 25 APRIL 2023**

08:00 - 08:45 Satellite Symposium sponsored by Janssen



**Title:** Switch or stick: a 360° perspective from the clinic

Speakers: Dr Tristan Barber, Consultant in HIV Medicine at the Ian Charleson Day Centre and Royal Free London NHS Foundation Trust and Honorary Associate Professor at the Institute for Global Health, UCL

Dr Shema Tariq, Honorary Consultant Physician in HIV/Sexual Health, CNWL NHS Foundation Trust and Senior Clinical Research Fellow, UCL Institute for Global Health

Mrs Mercy Shibemba, Affiliate of Penta Foundation UK



# Industry Satellite Symposia & Workshops

### **TUESDAY 25 APRIL 2023 - CONTINUED**

13:35 - 14:20 Workshop sponsored by Gilead Sciences



**Title:** Whose Role is it Anyway? 'Right people, right place, right time for the annual health review'

**Host:** Dr Naomi Sutton, Consultant Physician, Rotherham Sexual Health Services

Panellists: Mr Chris Hodgson, Lead HIV CNS, Central Lancashire

Mrs Madeline Brodie, Senior Support Worker, Infectious Diseases Department North Manchester General Hospital

Mr Asim Ali, Principal Pharmacist
– HIV, Sexual and Reproductive
Health (Guy's and St. Thomas' NHS
Foundation Trust) and Co-Chair of
London HIV Pharmacy Leads Group
(sub-committee to London HIV
Clinical Forum)

Miss LeaSuwanna Griffith – Positively UK

### **TUESDAY 25 APRIL 2023 - CONTINUED**

14:35 – 15:35 Satellite Symposium sponsored by ViiV Healthcare



**Title:** One year on – what have we learned about long-acting injectables? A panel discussion with different perspectives.

Speakers: Dr Iain Reeves, Consultant in HIV Medicine, Homerton University Hospital NHS Foundation Trust

Prof. Chloe Orkin, Barts Health NHS Trust and Queen Mary University of London

Fiona Clark, Specialist Pharmacist HIV & Sexual Health, Cardiff and Vale NHS Trust

Moses Shongwe, Lead Nurse HIV, Barts Health NHS Trust

Dr Alexander Margetts, Consultant in Clinical Psychology, Senior Tutor at Leicester University

Josh Sharples, Person living with HIV who is currently receiving 2-monthly long acting injectables

### **WEDNESDAY 26 APRIL 2023**

11:15 – 12:15 Satellite Symposium sponsored by MSD



**Title:** A multidisciplinary perspective on optimising HIV treatment regimens **Chair:** Dr Steve Taylor, Lead HIV Consultant, Birmingham Heartlands Hospital

Speakers: Dr Claire Dewsnap, President of BASHH, Sexual Health Consultant at Sheffield Teaching Hospital NHS Foundation Trust

Hasan Mohammed, Advanced Pharmacist Practitioner, Chelsea & Westminster Hospital NHS Foundation Trust

Jonathan Roberts, Senior HIV Testing co-ordinator, SHAC/ HIV, Royal Sussex County Hospital



# Welcome to Viatris

Viatris is a new healthcare company committed to empowering people in the UK to live healthier at every stage in their lives.





# Speakers Biographies

# Dr Hannah Alexander, Consultant in HIV & Sexual Health, North Middlesex Hospital, UK

Dr Hannah Alexander is the lead for re-engaging people who are not in care at the North Middlesex Hospital. She has a strong background in this having helped set up the South East London re-engagement project in 2020, funded by the Elton John AIDS Foundation. She also established one of the first A&E opt out HIV testing pathways at King's College Hospital in 2016 and helped introduce BBV testing in the A&E at the North Middlesex.



### Dr Victoria Appleby, Consultant Transplant Hepatologist, Leeds Liver Unit, UK

Dr Appleby graduated from University of Leeds in 2008 and completed postgraduate medical training in the Yorkshire and Humber deanery. Her MD, registered with Queen Mary University London concentrated on large scale case finding for viral hepatitis in migrant populations (as part of the HepFREE study). She has worked as a Consultant Transplant Hepatologist on the Leeds

Liver Unit since February 2021 and has an interest in viral hepatitis and the elimination strategy as well as portal hypertension and liver transplantation. Outside of work she is keen long distance (IRONMAN) triathlete.



# Dr Sanjay Baghani, Consultant physician/honorary senior lecturer in infectious diseases/HIV medicine, Royal Free London NHS Foundation Trust, UK

Dr Bhagani is a consultant physician in infectious diseases and HIV medicine with a special interest in the management of complex HIV infection, including difficult opportunistic infections and the management of viral hepatitis in HIV-infected patients.



### Dr Diana Barger, Research Fellow, University of Bordeaux – Inserm U 1219 Bordeaux Population Health Research Centre, France

Diana Barger is a public health researcher at the University of Bordeaux/Inserm U1219 Bordeaux Population Health Research Centre in France. She is interested in the development, validation and deployment of patient-reported outcomes (PROs) and health services and outcomes research.

Dr. Barger has been involved in research on HIV in Europe since 2013. Her doctoral research, supervised by Professors Fabrice Bonnet and François Dabis, aimed to develop and deploy new technology to capture PROs, including [health-related] quality of life in patients in long-term, hospital-based, HIV care. In her current research, she is using the French national claims database to understand how people living with HIV, half of whom are now over the age of 50, have been navigating the healthcare system beyond their hospital-based HIV consultations. This research aims to assess whether and how specific changes to national guidelines for the management of HIV have affected healthcare utilization patterns, costs and outcomes (e.g. retention in care, sustained viral suppression, quality of life) in people living with HIV. Previously, she worked with both Save the Children International and the United Nations Population Fund as an independent consultant supporting large-scale evaluations of multi-country health and human rights programmes.





# Professor Fiona Burns, Professor of Epidemiology & HIV, University College London, UK

Fiona Burns PhD, FRCP, is a Professor in Sexual Epidemiology and HIV at the UCL Institute for Global Health and the HIV Clinical Lead at the Royal Free Hospital. Her research interests are in the social and behavioural dimensions of HIV/STI epidemiology, with a particular interest in health

care access, engagement and social inequalities, as well as migrant health. She is Chair of the BHIVA Audit & Standards Committee and co-led the revision of the BHIVA Standards of Care for people living with HIV 2018. Fiona undertook her medical training at Otago University in New Zealand before moving to the UK in 1995.



### Professor Andrew Carr, Senior Staff Specialist in Clinical Immunology and Immunopathology, St Vincent's Hospital, Sydney, Australia

Professor Andrew Carr graduated from the University of New South Wales (UNSW), Sydney, in 1984, became a member of both the Royal Australasian College of Physicians and the Royal College of Pathologists Australasia in 1993, and completed his doctoral thesis on HIV-related

drug hypersensitivity in 1994. He has been at St Vincent's Hospital, Sydney, since 1989, where he is a clinical immunologist and immunopathologist and, until recently, Director of the Immunology and HIV Unit and Head of the Clinical Research Program, Centre for Applied Medical Research. He was appointed Professor of Medicine, UNSW, in 2006. He has authored more than 370 peer-reviewed publications. His main research interest is the complications of HIV therapy and antiretroviral adherence. In 2008, he was cited by Science as one of the top 10 HIV researchers worldwide.



### Dr Kate Childs, Consultant IN Sexual health and HIV Medicine, King's College Hospital NHS Foundation Trust, UK

Kate Childs is a Consultant in Sexual Health and HIV at King's College Hospital. She undertook a PhD on the subject of Hepatitis C in special populations at King's College London and is also appointed by the Institute of Liver Studies, running a weekly HIV/liver clinic. Within the field of HIV,

her main area of interest is in reengagement and removing barriers for PLWH to access HIV care. She co-led an Elton John AIDS Foundation sponsored South East London reengagement project, and the FTC peer mentorship quality improvement project in conjunction with GSTT and Metro charity. She aims to raise awareness of PLWH who are not in care and particularly advocate for patients affected by deprivation.



### Dr Daniella Chilton, HIV Clinical lead and Deputy Clinical Director, Guy's and St Thomas' NHS Foundation Trust

Dr Daniella Chilton is HIV Clinical lead at Guy's and St Thomas', specialising in young adults with HIV and those with metabolic co-morbidities. Leading the 'Living well' co-morbidity clinic, she has developed a special interest in lifestyle medicine and the delivery of personalised, patient-centred

care to support change. At trust level, Daniella is deputy clinical director, and is the clinical lead for the patient initiated follow up programme at GSTT.





### Dr Rageshri Dhairyawan, Consultant in HIV Medicine, Barts Health NHS Trust, UK

Dr Rageshri Dhairyawan is a Consultant in HIV Medicine at Barts Health NHS Trust, where she leads on tertiary HIV/hepatitis and HIV/lymphoma services and undertakes inpatient care. She is an Honorary Senior Lecturer at Queen Mary University of London as part of the SHARE Collaborative. Her research and advocacy focus on health equity, particularly at the intersection

of ethnicity and gender. She has held several national policy and charity roles, including BHIVA New Consultant Representative (2017-2019) and Chair of the BHIVA External Relations Subcommittee.



# Dr Doug Fink, Consultant Infectious Diseases, Royal Free hospital and University College London, UK

Dr Doug Fink is the principal research fellow at the Institute of Immunity and Transplantation at UCL. He is an honorary consultant in infectious diseases at the Royal Free hospital. His research focuses on innate immune responses to acute and chronic virus infection including HIV. He

founded the Nigerian Institute of Medical Research (NIMR)-UCL collaboration which investigates inflammatory non-communicable disease in people living with HIV in west Africa. He is the chair of the BHIVA international partnerships working group and recently sat on the treatment guidelines committee.



### Dr Kate Flanagan, ST5 Genito-urinary Medicine, King's College London, England

Dr Kate Flanagan graduated from the University of Nottingham Medical School in 2012. She commenced training in Genito-urinary medicine in 2017 and is currently an ST5 trainee at King's College Hospital.



# Dr Stuart Flanagan, Consultant Physician HIV & BBV Medicine, Mortimer Market Centre, CNWL NHS Foundation Trust

Dr Stuart Flanagan is a Consultant in GU/HIV & Blood Borne Virus (BBV) Medicine at CNWL NHS Trust's Mortimer Market Centre in Central London, and Honorary Consultant at University College London Hospital. He is the Viral Hepatitis Lead for CNWL Trust, and the NCL ODN

Primary Care Lead for Viral Hepatitis. Stuart is also Honorary Associate Professor at University College London. He completed an MD(Res) on Viral Hepatitis testing in Primary Care in 2020, and has research interests in Viral Hepatitis, BBV screening, Future HIV Services and Digital Care. He is chair of the BASHH HIV/BBV Special Interest Group and the organising committee for the annual BASHH HIV Masterclass conference. He also Medical Advisor to the board of CAPS-Positive Faith Charity. Stuart has been a medical broadcaster for the BBC (BBC Radio 1 Surgery, CBBC's Newsround, BBC Breakfast). He has written and presented BBC Radio 4 documentaries including The Path Of Least Resistance, on antimicrobial resistance, available to listen to via BBC iPlayer. Sex Talk, a podcast Stuart made in association with Public Health England and the Terrence Higgins Trust, is available to download from podcast platforms.





### Dr Keerti Gedela, Consultant Physician Chelsea & Westminster NHS (56 Dean Street); Lead for EDI, NIHR NWL CRN; Researcher (Global Health), Chelsea & Westminster NHS Foundation Trust

Dr Keerti Gedela is a Consultant Physician and researcher at 56 Dean Street, Chelsea & Westminster NHS, specialising in HIV/sexual health medicine and global health research. She is the lead for Equality, Diversity & Inclusion for the NIHR North West London Clinical Research Network and a lecturer at Imperial College. She's worked as an infectious diseases physician, researcher and lecturer in Southern Africa, India, Brazil and Indonesia; including technical and leadership roles in diverse healthcare settings within programme development, service and implementation research delivery, clinical care and education. She leads MRC and Wellcome-funded research within UK-Indonesian and wider global, multi-disciplinary partnerships. Her projects involve work with multi-sector organisations and stakeholders from WHO/UN agencies, Ministries of Health, NGO and commercial/creative agencies to local community organisations and patient groups. Her work focuses on clinical/social science research, health equality initiatives and public engagement to drive equitable, innovative and sustainable healthcare.



# Dr Qamar Ghafoor, Clinical Oncology Consultant, University Hospital Birmingham, UK

Dr Qamar Ghafoor is a Clinical Oncology Consultant and the Oncology Service Lead at University Hospital Birmingham, UK. He qualified from the University of Birmingham, UK in 2002. He trained within the West Midlands and was appointed as a Consultant Clinical Oncologist in

2011. Dr Qamar Ghafoor is an Honorary Lecturer at the University of Birmingham, UK. Dr Ghafoor specializes in the treatment of skin, lung cancers, and mesothelioma with chemotherapy, immunotherapy, targeted agents, and radiotherapy. He is the principal investigator for a number of national clinical trials and has published multiple papers in peer-reviewed journals, in addition to presenting at international conferences.



# Mark Ellerby-Hedley, Sexual Health Improvement Practitioner, Newcastle upon Tyne Hospitals, UK

Mark was diagnosed with HIV in November 1998 at the age of 33 so will be celebrating 25 year living well with HIV this year. At the time he worked as a supermarket manager in the North East of England, after disclosing his HIV status at work he experienced stigma and

discrimination by senior management which eventually led to him taking his employer to court linked to the Disability Discrimination Act. Mark has been married for 7 years and has been together with his partner for 24 years. Mark is very happy to talk about his lived experience of living with HIV and is also happy to answer any questions about those experiences.



### Dr Andrea Hearn, Consultant Psychiatrist, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, UK

Andrea Hearn worked initially as a research associate at the University of Newcastle upon Tyne where she gained her PhD in gastric physiology. She went on to study medicine and then started her training in psychiatry in 1995. She has worked in the field of addiction psychiatry since 1999.

She works in a community addiction service managing patients with both alcohol and drug use disorders with physical and mental health co-morbidities.







# Dr Rachel Hill-Tout, Clinical Lead BBV Opt-out Testing in Emergency Departments, London, NHS England, UK

Rachel Hill-Tout is an HIV and Sexual Health physician with an interest in expanding HIV and Blood-Borne Virus (BBV) testing in Emergency Departments and Primary Care. Rachel worked as an HIV consultant in London and, motivated by the devastating effects of late diagnosis of HIV, she

decided to pursue dual qualification in General Practice with a view to developing integrated models for HIV testing, care and prevention in front line services. Rachel worked on piloting and implementation of opt out HIV testing in the Medical Admissions Unit in Croydon University Hospital and undertook a fellowship with Public Health England, analyzing hepatitis B vaccination coverage in gay, bisexual and men who have sex with men in response to outbreaks of acute hepatitis B. Rachel is the NHS England Clinical Lead for HIV opt out testing in Emergency Departments (London), supporting the nationally funded initiative to implement HIV opt out testing in Emergency Departments in the highest prevalence areas in England. She is a member of the National HIV Action Plan Implementation Steering Group, the London Primary Care BBV Testing Steering Group. She is in her final year of GP training in Hackney, London.



### Stephen Hindle, Project Manager Opt Out HIV testing, NHS England, UK

Stephen is the project manager for the Emergency Department Blood Borne Virus testing programme in England. Prior to this he worked for the Elton John AIDS Foundation, where he was Performance Manager for the EJAF Social Impact Bond Zero HIV project, which worked with partner organisations in SE London to promote HIV testing and reengagement to care in

emergency departments, primary care and community organisations. He has over twenty years' experience in health programme management and service development both in the UK and Africa.



### Professor Susan Hopkins, Chief Medical Advisor, UK Health Security Agency (UKHSA)

Professor Susan Hopkins is the Chief Medical Advisor at the UK Health Security Agency (UKHSA). In this capacity she leads the Clinical and Public Health Group whose objective is to provide professional health security, clinical and public health leadership. Susan is also a Professor of Infectious Diseases and Health Security at University College London and continues to work

clinically as a consultant in Infectious Diseases and Microbiology at the Royal Free London NHS Foundation Trust.



# Dr Ewan Hunter, Consultant in Infectious Diseases, The Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK

Dr Ewan Hunter has been involved in HIV medicine since 2006, working in the North East of England, London and Tanzania. He studied epidemiology at the London School of Hygiene and Tropical Medicine and has a PhD with the Institute of Health and Society at Newcastle University.

He is currently a Consultant in Infectious Diseases with the Newcastle-upon-Tyne Hospitals NHS Foundation Trust, where he is responsible for delivering treatment and care to people living with HIV in North Cumbria. Alongside his clinical work in the NHS, he maintains educational and professional links with colleagues in Tanzania. He leads a module of rural health placements on the East African Professional Diploma in Tropical Medicine and Hygiene, which has focused on access to care for people living with HIV in eastern rural Tanzania, and in 2022 he completed a BHIVA/Gilead International Exchange Fellowship with colleagues from the Kilimanjaro region, which had been delayed by the COVID pandemic. Closer to home, he works with local third sector partners including Blue Sky Trust and Eyes Open to improve education and support for people living with HIV in our community and to tackle the stigma experience by people living with HIV, including in healthcare settings.





### Ian Jackson, Director of Planning and Contracting, NHS England, London

Ian is the Commissioning Director for the London Specialised Commissioning Directorate at NHS England and has worked in the NHS for 20 years. He is also the Programme Director for the HIV and Hepatitis Opt out testing programme, which is being implemented in all of London's 28 Emergency Departments and a member of the London Fast Track Cities Leadership Group.

Through the COVID-19 Pandemic Ian was redeployed to the role of Critical Care Programme Director for London. Ian is on the Fast Track Cities Leadership Group for London and is also a trustee of Rethink Mental Illness.



# Dr Veronique Martin, Principal HIV/STI Prevention and Surveillance Scientist, UK Health Security Agency, UK

Veronique Martin is a Principal HIV/STI Prevention and Surveillance Scientist in the HIV and AIDS Reporting Section at the UK Health Security Agency. She is a mixed methods researcher with a PhD in Cell Biology and an MSc in Public Health. With over ten years of experience in public

health and health services research, Veronique's current research interests include monitoring engagement in care and health outcomes, and experience of stigma, among people living with HIV.



### Dr Orla McQuillan, Consultant in Genitourinary Medicine, Northern Sexual Health, Manchester Foundation Trust, UK

Orla McQuillan works as a Consultant in Genitourinary Medicine within the Northern Sexual Health service, Manchester Foundation Trust (MFT). She is the site lead for Manchester Royal Infirmary Emergency Department (ED) HIV and Hepatitis C testing project which started in

December 2021 and is now operational across all 3 ED departments in MFT under the ED testing working group. She has special interests in outreach and HIV in pregnancy and is the Key Opinion Leader for the Manchester Fast Track Cities Initiative.



# Miss Rose Mower, Clinical Nurse Specialist HIV, Guy's & St Thomas' NHS Foundation Trust, UK

Rose Mower is a HIV CNS who joined Guy's & St Thomas' Foundation Trust in 2021. Her primary interest is working with marginalized patients to ensure this cohort is not disadvantaged by conventional models of care. She is the CNS lead for PLWH not in care and has successfully

helped support many of vulnerable patients to attend clinic and re-commence treatment.



### Ruth Muko, Digital Artist & Oral History Interviewer, Chiva, London, England

Ruth Muko is a London-based Digital Artist and Oral History Interviewer. She is currently partnered with Chiva, working on the Positively Spoken project. A former trained architect, Ruth uses design to embrace cultural and social differences, and improve human experience.





### Dr Tomilola Musari-Martins, Clinician, Nigerian Institute of Medical Research, Nigeria

Dr. Tomilola Musari-Martins is a graduate of medicine at the Olabisi Onabanjo University, Ogun State, Nigeria. She is a practicing clinician at the Nigerian Institute of Medical Research, with many years of clinical and research experience. She is a resilient critical thinker and problem-solver who has dedicated the past 10 years of her practice to providing evidence-based

clinical services to people living with HIV, especially the vulnerable cohort (children, adolescents, and young adults) at the Clinical Science department of the Institute. She is a member of infection prevention and control, staff welfare, and quality improvement committees in her department. She also assists in the coordination of a multi-collaborative NIH grant aimed at integrating youth participation to promote HIV self-testing among young people in Nigeria. She has co-authored several scientific papers in peer-reviewed journals.



### Mrs Hajra Okhai, Research Statistician, Institute for Global Health, University College London, UK

Hajra is a Research Statistician based at the Institute for Global Health, University College London since 2018. She has collaborated on designing, analysing and publishing a range of research projects exploring clinical and psychological outcomes using large, representative datasets of

people living with HIV in the UK including the UK Collaborate HIV Cohort (CHIC), Positive tRansltions through Menopause (PRIME) and Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) studies. Hajra's present research focusses on depression and access to mental healthcare amongst people ageing with HIV. Recently, she has been collaborating with the British HIV Association (BHIVA), National Nurses HIV Association (NHIVNA) and British Psychological Society (BSP) to lead on the analysis for the stakeholder consultation.



# Professor Nicholas Paton, Professor of Infectious Diseases, National University of Singapore, Singapore / London School of Hygiene and Tropical Medicine, UK

Nicholas Paton trained in Medicine and Infectious Diseases in Cambridge, Sydney and London, and in Epidemiology at the London School of Hygiene and Tropical Medicine. He holds a joint appointment as professor of infectious diseases at the National University of Singapore and

at the London School of Hygiene and Tropical Medicine. His research interests are optimisation of HIV and tuberculosis treatment for the public health approach in resource-limited settings. He is the Chief Investigator of the NADIA trial (second-line HIV treatment; done in 7 sites in Uganda, Kenya and Zimbabwe) and the Scientific Lead of the CARES trial (comparing long acting cabotegravir/rilpivirine with standard combination ART at 8 sites in Uganda, Kenya and South Africa). In Singapore he leads a programme of TB trials focused on trials of host-directed therapies for TB; and is the Chief Investigator on the TRUNCATE-TB trial (a strategy trial of 2 months of treatment for drug-susceptible TB done across a network of 18 sites in Asia and Africa).





### Professor Neil Poulter, Chair in Preventive Cardiovascular Medicine, Imperial College London, UK

Professor Neil Poulter qualified at St Mary's Hospital, London, in 1974, following which he trained in General Medicine. He then spent 5 years in Kenya co-ordinating a collaborative hypertension research programme at the Wellcome Trust Research Laboratories in Nairobi. In 1985 he gained

an MSc in Epidemiology with distinction at the London School of Hygiene and Tropical Medicine. Following this he was Co-PI of the WHO Oral Contraceptive case-control Study at University College London Medical School. In 1997 he was appointed Professor of Preventive Cardiovascular Medicine at Imperial College London, where he is currently co-Director of the International Centre for Circulatory Health and Founding Director of the Imperial Clinical Trials Unit. He is an Honorary Consultant Physician and Epidemiologist at the Peart-Rose (CVD Prevention) Clinic based at Hammersmith Hospital, London, where he is actively involved in the treatment of patients with hypertension and related problems. He was President of the British Hypertension Society from 2003-2005 and was the President of the International Society of Hypertension from 2016-2018. In 2008, he was elected as one of the Inaugural Senior Investigators of the NIHR and also elected as a fellow of the Academy of Medical Sciences in 2009. He has contributed chapters to several major textbooks and published over 650 papers in peer-reviewed medical journals, including co-authoring several sets of national and international guidelines. Professor Poulter was identified as being among the top 1% most cited academics in clinical medicine in 2014 (Thomson Reuters Highly Cited Researcher report) and among the top 0.1% most cited researcher between 2008-2021 (Web of Science Group Highly Cited Researcher). He has played a senior management role in several international trials including the ASCOT, ADVANCE, EXSCEL, DEVOTE LEADER and CREOLE trials; other research activities include the optimal investigation and management of essential hypertension and dyslipidaemia; the association between birth weight and various cardiovascular risk factors; the cardiovascular effects of exogenous oestrogen and progesterone; the prevention and aetiology of type 2 diabetes and abdominal aortic aneurism; and ethnic differences in cardiovascular disease. He is the Chief Investigator of the May Measurement Month, an annual global blood pressure screening campaign initiated by the International Society of Hypertension.



### Dr Wendy Rickard, Oral Historian, Chiva, UK

Wendy Rickard is an oral historian who has been involved in capturing the oral history of HIV and AIDS over 27 years, working closely with the British Library Sound Archive and currently with Chiva. Wendy is an Associate Researcher in The Oral History Collective, School of History, Classics & Archaeology, Newcastle University. She formerly worked on Service User Involvement

in Health Research at Folk.us, University of Exeter, as a Research Reader in Public Health at London South Bank University, Senior Lecturer in Health Promotion at University of East London and various policy research roles in the NHS and voluntary sectors.



### Dr Melanie Rosenvinge, Consultant in GU Medicine, Lewisham and Greenwich NHS Trust, UK

Dr Melanie Rosenvinge is a Consultant in GU& HIV Medicine. She is particularly proud of the year that she spent running a large HIV service in Epworth, Zimbabwe for Medicins Sans Frontieres. In 2014 she started work at University Hospital Lewisham (UHL) where she has set up

routine HIV testing in ED, developed the HIV in pregnancy service and concentrated on improving relations with primary care. She is currently focused on initiatives to re-engage those who discontinue HIV treatment and keep them in care.





# Dr Sarah Rutter, Consultant Clinical Psychologist, North Manchester General Hospital HIV Service, UK

Sarah Rutter is a Clinical Psychologist based in the HIV Service at North Manchester General Hospital, and is also the clinical lead for HIV psychology services across the Manchester University NHS Foundation Trust footprint. Sarah was also chair of the British Psychological

Society's HIV and Sexual Health Faculty for four years and continues to sit on the committee. She has been involved in, and has often co-facilitated various projects within the field of HIV, including the writing and updating of national care standards, audit of the HIV psychological standards, and the development of a psychological support training package for healthcare professionals working within HIV. She has also co-edited and contributed to books relating to the topics of psychological care in HIV. She is an honorary lecturer at the University of Liverpool, and provides HIV specific teaching and training to Trainee Clinical Psychologists across the North West region and HIV and sexual health services across the UK.



# Professor Caroline Sabin, FMedSci, Professor of Medical Statistics and Epidemiology, University College London, UK

Caroline Sabin is Professor of Medical Statistics and Epidemiology at University College London (UCL) and is the Director of the NIHR Health Protection Research Unit in Blood-Borne and Sexually Transmitted Infections at UCL. Caroline's interests are in describing the natural history

of HIV infection, identifying prognostic markers and describing responses and adverse events to cART. She established the UK Collaborative HIV Cohort (UK CHIC) Study, was the principal statistician and co-lead for the D:A:D Study and is the co-principal investigator for the POPPY study, a large cohort set up to investigate the associations of ageing and HIV in the UK and Ireland. Since the start of 2020, she has been one of the two Editors-in-Chief of HIV Medicine, BHIVA's flagship journal.



# Dr Ann Sullivan, Consultant Physician, Chelsea and Westminster Hospital NHS Foundation Trust, UK

Dr Ann Sullivan trained in Hobart and Sydney. She is an HIV Consultant at Chelsea and Westminster Hospital, Honorary Consultant at UKHSA and Honorary Senior Lecturer at Imperial College. Her interests include PrEP and HIV epidemiology, testing and Standards of Care. She sits


on the BHIVA audit and standards sub-committee and is Secretary of EACS.



#### Dr Becky Walker, Engagement Officer, Blue Sky Trust, UK

Becky is a wife, mother, supporter, educator, peer mentor, and advocate. She is an Engagement Officer with Blue Sky Trust, a HIV support charity in Newcastle. She is also a member of UK-CAB. She's been living with HIV for 15 years and has been using her experience of living with HIV to try and change people's perception about HIV, improve awareness, educate, and tackle HIV stigma

and discrimination.



Laura Waters is a HIV & Sexual consultant and HIV lead at The Mortimer Market Centre, London. She is the National Specialty Advisor for HIV, chairing the group that advises NHS England on HIV treatment and the immediate past chair of the British HIV Association (BHIVA). She has

published & presented widely, is a trustee for The Food Chain and previously for the Terrence Higgins Trust and She teaches regularly at local, regional and national level, including on HIV courses for University College London and the London School of Hygiene & Tropical Medicine.





### Lucy Wood, Lead Nurse for HIV testing in ED at University Hospital Lewisham, Lewisham and Greenwich NHS Trust, UK

Lucy is a full-time nurse with the HIV team at University Hospital Lewisham, Lewisham & Greenwich NHS Trust, in South East London. Having always had an interest in HIV care, she previously lived in Uganda for 5 years with her husband and 4 children where they worked with a team

of volunteers to pioneer an NGO working with children living with HIV. She now leads on HIV testing in the Emergency Department and on re-engaging people in their HIV service who are not in care or are at risk of disengaging. She has a genuine interest in breaking down the barriers that prevent people from living well with HIV.



# Dr Melvina Woode Owusu, Research & Evaluation Consultant, Purple Pen Research & Evaluation Consulting, England, UK

Melvina is a Research and Evaluation Management Consultant and Honorary Senior Research Fellow at the University College London. Stimulated by her study of medical anthropology at Durham University, and later her doctoral study in epidemiology, Melvina is committed to

incorporating both community and population-level perspectives when supporting researchers and providers to embed an inclusive approach to design, delivery and dissemination. Her 15 years' of experience in sexual and public health includes surveillance, promotion & management in local, national and international projects and organisations, including the WHO, ECDC, and UNAIDS. Melvina is also Trustee of the Race Equality Foundation.



# SAVE THE DATE

# 2023 Autumn Conference Friday 24th November 2023 LONDON











# **Sponsors and Exhibitors**

# **BHIVA Platinum Sponsors and Exhibitors 2023**



Gilead Sciences Ltd 280 High Holborn London WC1V7EE



MSD Ltd 120 Moorgate London EC2M 6UR



ViiV Healthcare UK Ltd

Stockley Park West Uxbridge Middlesex **UB11 1BT** 

## **BHIVA Bronze Sponsor 2023**



Viatris

Building 4, Trident Place, Mosquito Way, Hatfield AL10 9UL

BHIVA is grateful to their sponsors and commercial exhibitors for their continued support. The funds provided by sponsors and commercial exhibitors are used solely for the educational content of BHIVA events and are not allocated to BHIVA's social events.

### **Exhibitors**



Blue Sky Trust



British HIV Association



Chars



Chiva

👭 **inform** health

Inform Health















HIV Trainee Association (HIVTA)



Integrated Screening Outcomes Surveillance Service (ISOSS)



Invitech-OraQuick



Janssen



Kora Healthcare





NAM aidsmap



National AIDS Trust





Sophia Forum



Positive+1



UKHSA (UK Health Security Agency)



Mildmay Mission Hospital

Positively UK



Saving Lives



Waverley Care





### www.blueskytrust.org

#### **Blue Sky Trust Stand 2**

For over 30 years, Blue Sky Trust has supported and connected people living with HIV in the North East of England and Cumbria. We aim to improve the health, wellbeing and quality of life of people living with HIV, whilst also challenging the stigma associated with it. Through peer mentoring, courses, peer support groups, empowerment programs, 1-2-1 support and volunteering opportunities, people living with HIV have the opportunity to develop their confidence, knowledge, skills and resilience and to connect with a supportive, thriving and diverse community.



www.bhiva.org

#### **BHIVA Stand 20**

BHIVA is the leading UK association representing professionals in HIV care. Since 1995, we have been committed to providing excellent care for people living with and affected by HIV. BHIVA is a national advisory body on all aspects of HIV care and we provide a national platform for HIV care issues. Our representatives contribute to international, national and local committees dealing with HIV care. In addition, we promote undergraduate, postgraduate and continuing medical education within HIV care.



#### www.chiva.org.uk

#### Chiva Stand 4a

Chiva carries out direct support work with children, young people and families living with HIV, and works with health professionals, to ensure that children and young people living with HIV have the treatment and care, knowledge, understanding, skills and wider support needed to live well and achieve their greatest potential. Chiva works with people living with HIV who have transitioned to adult care up to age 25 and there are peer opportunities beyond this age too.



#### **PLATINUM SPONSOR**



### www.gilead.co.uk

# Gilead Sciences Stand 6 Gilead non promotional Stand 8

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, millions of people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company's manufacturing partners.





www.i-base.info www

www.ukcab.net

### HIV i-Base and UK-CAB Stand 3

HIV i-Base is a treatment activist group. We are committed to providing timely and up to date information about HIV treatment to HIV positive people and to health care professionals. This includes technical and non-technical publications (all also available online, many in other languages) and a Q&A service (by phone, email and online).

Founded in 2002, the UK Community Advisory Board (UK-CAB) is a network of 700+ treatment activists from 100+ HIV community organisations. The UK-CAB provides a unique collective community voice and expertise beyond the individual for the many clinicians, researchers and policy makers who actively seek community views.





### www.hivpreventionengland.org.uk

#### **HIV Prevention England - THT Stand 15**

HIV Prevention England (HPE) is the national HIV prevention programme for England. It delivers a nationally co-ordinated programme of work for people working in HIV prevention and sexual health, in particular those working with gay and bisexual men, people of Black African ethnicity, and other emerging populations affected by HIV. Complementing locally commissioned activity, HPE brings together campaigns, including National HIV Testing Week, local activation partners, and a capacity and skills development programme. HPE is funded by the Office of Health Improvement and Disparities and managed by Terrence Higgins Trust.





# www.hivta.org.uk

#### **HIV Trainee Association (HIVTA) Stand 19**

The HIV Trainee Association exists to support the learning and development of doctors in training with an interest in HIV medicine, including infectious diseases (ID) trainees, Genitourinary medicine (GUM) trainees and those in internal medicine who have responsibility for HIV patients. Membership is open to Doctors and Research Fellows in all training grades. The association acts as an educational facility and provides all members with a national network for mutual support and advice.



#### www.informhealth.co.uk/hiv

#### Inform Health Stand 4b

Inform Health are passionate about unlocking the benefits technology has to offer HIV services. Our Inform HIV platform brings together, in one system, the tools required to support delivery of a modern HIV service. Inform HIV provides services with everything they need to go from fulfilling business critical data returns and electronic patient records, to technology for HIV patients and technology to support MDT meetings for HIV.





www.ucl.ac.uk/isoss www.ucl.ac.uk/chars

# Integrated Screening Outcomes Surveillance Service (ISOSS) & Children's HIV and AIDS Reporting Service (CHARS) Stand 7

The Integrated Screening Outcomes Surveillance Service (ISOSS) is part of the NHS Infectious Diseases in Pregnancy Screening Programme (IDPS). Based at UCL Great Ormond Street Institute of Child Health (GOS ICH), ISOSS carry out the national monitoring of HIV, syphilis and hepatitis B in pregnant women and children. Long-term paediatric HIV surveillance is carried out by the Children's HIV and AIDS Reporting System (CHARS) for NHS England and NHS Improvement and the UK Health Security Agency's National Infection Service. Also based at GOS ICH, CHARS follows all children and young people living with HIV who access paediatric services in England.





#### www.oralhivtest.co.uk

#### **Invitech-OraQuick Stand 12**

Invitech is a trusted supplier to the NHS and public health providers across the United Kingdom. We are a privately held distribution business, founded in 2008, certified to ISO9001:2015, and representing a number of global brands. Invitech has been the UK partner of OraSure since 2012 supplying the OraQuick HIV 1/2 Antibody Test, the world's first point of care test for the detection of HIV antibodies in oral fluid. With over 75 million tests used worldwide we are delighted that the test is now available for Self-Testing and is exclusively available via Invitech. For more information visit www.oralhivtest.co.uk



## www.janssen.com/uk

#### Janssen Stand 9

Our Work in Infectious Diseases and Vaccines At Janssen, our fight against infectious diseases is a global effort. From viral hepatitis and human immunodeficiency virus (HIV) to pathogens of global concern. We strive to discover and develop novel therapeutics and vaccines to help prevent, treat, and ultimately cure infectious diseases worldwide, improving treatment outcomes and patients' lives. With goals like these, there's no time to waste. That's why the team focuses on internal discovery and world-class development of therapeutics and vaccines whilst seeking out partnerships across the world to connect our expertise with others. We believe these problems can be conquered the same way all of humanity's greatest problems have been solved: persistent effort and game-changing innovation.



#### www.korahealthcare.com

#### Kora Healthcare Stand 0

Kora Healthcare is pleased to present its sexual health product, Catephen® (https://www.medicines.org.uk/emc/product/1894). This is licensed for the cutaneous treatment of external genital and perianal warts and is included in the BASHH guidelines (https://www.bashhguidelines.org/current-guidelines/skin-conditions/anogenital-warts-2015/). For more information we welcome a visit at our stand.





#### www.mildmay.nhs.uk

#### Mildmay Mission Hospital Stand 13

Mildmay Mission Hospital is a charitable hospital that has been at the forefront of specialist HIV care and service provision since 1988. Mildmay began as a charitable Christian institution over 160 years ago. It has specialised in HIV for over 30, and continues to deliver quality care and treatment, prevention work, rehabilitation, training, education and health strengthening in the UK and East Africa. In 2020, Mildmay started a ground-breaking service providing step-down, rehabilitative healthcare for people who are homeless or rough-sleeping and recuperating from illness or injury. We became London's primary COVID-Care Centre for this cohort and for HIV patients.

#### **PLATINUM SPONSOR**



#### www.msd-uk.com

#### MSD Stand 5

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on Twitter, LinkedIn, Instagram, YouTube, and Facebook.



HIV & AIDS - sharing knowledge, changing lives

www.aidsmap.com

#### NAM aidsmap Stand 22

NAM aidsmap works to change lives by sharing information about HIV & AIDS. We believe independent, clear and accurate information is vital in the fight against HIV & AIDS. On aidsmap.com, we publish the latest HIV news, scientific research from the world's leading HIV conferences, clear and reliable information on all aspects of HIV, broadcasts and digital media and translations and adaptions of our resources. We also offer a patient information subscription scheme, where clinics and patients can access our printed and digital booklets and leaflets, factsheets and online interactive tools.





www.nat.org.uk

#### National AIDS Trust Stand 21

National AIDS Trust - We are the UK's HIV rights charity. We work to stop HIV from standing in the way of health, dignity, and equality, and to end new HIV transmissions. Our expertise, research, and advocacy secure lasting change to the lives of people living with and at risk of HIV.

# *P*ositive<sup>+1</sup>

### www.positiveplusone.com

#### Positive+1 Stand 1

Positive+1 is the exciting new social & dating platform designed for people living with, and affected by HIV.

A safe and secure community, where you can find connection, education and support.

Our unique platform and tools will guide you through your journey with HIV.

Make new friends, learn from engaging content and find local support & events.

HIV sucks, but living with HIV doesn't have to.

To learn more and discuss a partnership with us, please visit our stand (1) or drop us an email: Hello@ positive plusone.com



www.positivelyuk.org

#### Positively UK Stand 14

Positively UK provides peer-led support, advocacy and information to anyone living with HIV in the UK, to effectively manage any aspect of their diagnosis, care and life with HIV. Working in partnership with the NHS, we provide integrated peer support within 16 clinics across London. We offer training to people with HIV to deliver high quality and effective peer support and collaborate with clinics and voluntary organisations around the UK to establish peer support programmes. We want all people living with HIV to have access to peer-led support.





#### www.savinglivesuk.com

#### Saving Lives UK Stand 16

We are a national HIV, Hepatitis and Sexual Health Awareness Charity

#### Our Aims:

To deliver public health campaigns for HIV, Hepatitis and sexual health

Increase awareness

Increase testing

Normalise HIV TESTING in hospitals, GP practices and in general to the public

Helps reduce late diagnosis

Reduce transmission

Reduce stigma - through education and communication

We work to achieve this through:

- Health promotion activities
- Sharing and providing health promotion materials
- Communicating through social media and traditional media
- Providing FREE HIV postal testing kits

We will keep working until testing is routine – and anyone who needs treatment can get it.



### www.sophiaforum.net

#### Sophia Forum Stand 18

**Sophia Forum** is a UK based Charity with a national and international reach. We promote and advocate for the rights, health, welfare and dignity of women living with and at risk of HIV through research, raising awareness and influencing policy.

#### Our vision:

A world where nothing stands in the way of all women living with HIV enjoying the right to a dignified, fulfilled and healthy life.

#### Our mission:

We exist to empower all women living with HIV to reach their full potential, and ensure their voices are heard and their needs prioritised, within the health sector and wider society.

We make sure women are meaningfully involved in all our work. Our CEO is a woman living with HIV, our one member of staff is a woman living with HIV, and our Board is also representative of women living with HIV.



## www.gov.uk/government/organisations/uk-health-security-agency

#### UK Health Security Agency (UKHSA) Stand 10

The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. UKHSA is an executive agency, sponsored by the Department of Health and Social Care.



#### **BRONZE SPONSOR**



# www.viatris.com/en-gb/lm/united-kingdom

#### **Viatris**

Viatris is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries. Viatris' portfolio comprises over 1,400 approved molecules across a wide range of therapeutic areas; including globally recognized complex generic and branded medicines.

#### **PLATINUM SPONSOR**



#### www.viivhealthcare.com

#### ViiV Heathcare UK Stand 11

We are ViiV Healthcare: A specialist pharmaceutical company 100% dedicated to HIV medicines and research, and completely focused on people living with HIV and AIDS. In the last 30 years, the world of science and the HIV and AIDS community have worked together to control the HIV epidemic. Right now, we face a new wave of challenges, still... we have to keep going. We are here until HIV and AIDS aren't.



#### www.waverleycare.org

### Waverley Care Stand 17

Waverley Care is Scotland's leading HIV and hepatitis C charity, and everything we do is guided by the experiences of the people we work with – this ranges from shaping the services we deliver through to how we influence national policy around sexual health and blood borne viruses. Our vision is for a Scotland where no one faces HIV alone, we will achieve this by fighting stigma and empowering people living with HIV to live full and healthy lives.



# Speaker's conflicts of interest

Hannah Alexander - none

Victoria Appleby - none

Sanjay Baghani -

Diana Barger - none

**Fiona Burns** – Fiona Burns has received speaker fees from Gilead Sciences Ltd.

Laura Byrne - none

Andrew Carr – Andrew Carr has received research funding from Gilead Sciences, MSD and ViiV Healthcare; lecture and travel sponsorships from Gilead Sciences and ViiV Healthcare; and has served on advisory boards for Gilead Sciences, MSD and ViiV Healthcare.

**Kate Childs** – Kate Childs was a speaker at Gilead Sciences engagement event.

**Daniella Chilton** – Daniella Chilton has received grants from Gilead Sciences, speaker fees from Jansen and ViiV Healthcare, and Advisory board fees for Jansen, ViiV Healthcare and Gilead Sciences.

**Rageshri Dhairyawan** – Rageshri Dhairyawan has received consultation fees from ViiV Healthcare and consultation and speaker fees from Gilead Sciences.

Mark Ellerby-Hedley - none

Doug Fink - none

Kate Flannagan – none

**Stuart Flanagan** – Stuart has received travel bursaries, conference bursaries and honoraria from Gilead Sciences and ViiV Healthcare.

Keerti Gedela - none

**Qamar Ghafoor** – Dr Ghafoor has received honoraria for academic presentations for: Astrazeneca, Roche, Chugai, Pfizer.

Andrea Hearn - none

**Rachel Hill-Tout** – Rachel Hill-Tout has received speaker fees, conference registration and travel grants from Gilead Sciences in 2022.

Stephen Hindle - none

#### Susan Hopkins

- NIHR HPRU Oxford and Imperial
- Royal Free London
- University College London

Ewan Hunter - none

lan Jackson - none

Orla McQuillan – none

Veronique Martin - none

Rose Mower - none

Ruth Mukonoweshuro - none

Tomilola Musari-Martins - none

**Nicholas Paton** – Nicholas Paton has received the following from Janssen: Research grants for NADIA, CARES and TRUNCATE-TB trials paid to institution, and personal speakers fees.

Neil Poulter – Neil Poulter has received financial support from several pharmaceutical companies which manufacture BP-lowering agents, for consultancy fees (Servier, Aktiia), research projects and staff (Servier, Pfizer) and for arranging and speaking at educational meetings (AstraZeneca, Lri Therapharma, Napi, Servier, Sanofi, Eva Pharma, Pfizer, Emcure India, Dr Reddy's Laboratories and Zydus). He holds no stocks and shares in any such companies.

Sarah Rutter – none

**Caroline Sabin** – Caroline Sabin has received funding for membership of Data Safety and Monitoring Boards, Advisory Boards and for preparation of educational materials from Gilead Sciences, ViiV Healthcare, Jansson-Cilag and MSD.

Ann Sullivan - none

Becky Walker - none

**Laura Waters** – Laura Waters has received speaker/advisory fees: ViiV Healthcare, MSD, Janssen, Gilead Sciences, Pfizer. Laura Waters is an investigator on trials for Gilead Sciences, ViiV Healthcare, & Janssen.

Wendy Rickard - none

**Melanie Rosenvinge** – Melanie has received speaker fees from the pharmaceutical company, Gilead Sciences.


**Lucy Wood** – Lucy has previously received speaker fees from Gilead Sciences.

Melvina Woode Owusu - none

# **BHIVA 2023 Spring Conference**

Monday 24th - Wednesday 26th April 2023









#### **Exhibitors**

- **0.** Kora Healthcare
- 1. Positive+1
- 2. Blue Sky Trust
- 3. HIV i-Base and UK-CAB
- 4a. Chiva
- **4b.** Inform Health
- **5**. MSD
- 6. Gilead Sciences
- 7. Integrated Screening Outcomes Surveillance Service (ISOSS) & Children's HIV and AIDS Reporting System (CHARS)
- 8. Gilead non-promotional stand
- **9.** Janssen
- **10.** UK Health Security Agency (UKHSA)
- 11. ViiV Healthcare
- 12. Invitech-OraQuick
- 13. Mildmay Mission Hospital
- **14.** Positively UK
- **15.** HIV Prevention England THT
- **16.** Saving Lives
- 17. Waverley Care
- **18.** Sophia Forum
- 19. HIV Trainee Association (HIVTA)

# Level 1

- 20. British HIV Association
- 21. National AIDS Trust
- 22. NAM aidsmap


BHIVA Spring Conference 2023

Mon 24th - Wed 26th April 2023

# **BHIVA 2023 Spring Conference**

Monday 24<sup>th</sup> - Wednesday 26<sup>th</sup> April 2023

Sage Gateshead - St Mary's Square, Gateshead





### Level 1

20. British HIV Association

21. National AIDS Trust

22. NAM aidsmap



BHIVA Spring Conference 2023

Mon 24<sup>th</sup> - Wed 26<sup>th</sup> April 2023